Folic acid modified norcantharidin stealth niosome and preparation method thereof
The technology of norcantharidin and folic acid is applied to the preparation of vesicles and the field of folic acid-modified invisible vesicles, which can solve the problems of easy hydrolysis, low drug bioavailability, and low norcantharidin, and achieves improved efficacy, The effect of high efficiency and low toxicity in the treatment of cancer and enhanced anticancer activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0047] Example 1 Preparation and verification of poloxamer 407-cholesterol
[0048] 1. Preparation and characterization of poloxamer 407-cholesterol:
[0049] 1.1. Preparation of poloxamer 407-cholesterol
[0050] According to macromolecular substances such as PEG and Poloxamer 407, which have terminal -OH, the synthetic route can be adopted: PEG-OH+(CH 3 CO) 2 O+CH 3 SOCH 3 → PEGOCH 2 CHO yields polymer acetals (called polymer-aldehydes). Namely: Weigh 5.123g of Poloxamer 407 into a 50ml round bottom flask, add 0.4g of acetic anhydride and 15ml of dimethyl sulfoxide (DMSO), and react at RT for 30h with electromagnetic stirring, drop into 150ml of anhydrous ether, shake well, Add dichloromethane dropwise to make the solution homogeneous, then add an appropriate amount of diethyl ether to precipitate, place at 4°C until the precipitate is completely precipitated, filter under reduced pressure, and dry in vacuum to constant weight to obtain a white loose solid: Poloxamer ...
Embodiment 2
[0069] Example 2 Preparation and Analysis of Folic Acid Modified Norcantharidin Stealth Vesicle Novel Drug Delivery System
[0070] 3. Preparation of a novel delivery system of folic acid-modified norcantharidin stealth vesicles
[0071] 3.1 Preparation of folic acid-modified norcantharidin invisible vesicle suspension (abbreviation: folic acid vesicle)
[0072] Each milliliter suspension contains 3.8 mg of norcantharidin, 20.0 mg of poloxamer 407-cholesterol (a), 1.2 mg of folic acid-polymer (b), and 29.4 mg of surfactant (c). Carrier materials a, b, and c are completely dissolved with organic solvents, mixed with norcantharidin for ultrasonication, and then mixed with PBS preheated at 60°C by injection method, stirred at 20-70°C and ultrasonicated until the organic solvent volatilizes Get it later.
[0073] 3.2 Preparation of folic acid modified norcantharidin / Rd B stealth vesicle suspension (abbreviation: folic acid vesicle’)
[0074] Adopt "3.1" method, but add fluoresc...
PUM
Property | Measurement | Unit |
---|---|---|
melting point | aaaaa | aaaaa |
particle size | aaaaa | aaaaa |
thickness | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com